Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets slip
Fri, 28 Mar 01:30 pm

Indian share markets continued to slip in the post-noon trading session and are trading close to the dotted line. Barring FMCG and capital goods, all the sectoral indices are trading in the green with realty, power and oil & gas stocks being the biggest gainers.

BSE-Sensex is up 11 points and NSE-Nifty is trading 15 points up. BSE Mid Cap is trading 1.1% up and BSE Small Cap index is trading up by 0.8%. The rupee is trading at 60.1 to the US dollar.

Retail stocks are trading mixed with Shopper's Stop and Future's Retail being the major gainers whereas Koutons Retail and Titan Industries are trading in the red. As per a leading financial daily, Titan Industries is set to benefit from the recent move by Reserve Bank of India (RBI) to allow it to hedge its gold inventory as well as currency exposure in the international exchanges. Titan borrows to fund its international gold purchases and is subject to currency risk as well as fluctuations in gold prices. This is expected to reduce the net interest cost of debt to finance gold purchases and improve profit margins. As per the company, its effective interest cost will be 3.5%-4% from April as compared to 10% currently. For the December 2013 quarter, the company's sales were down by 11% and operating margin contracted by 0.6% to 7.8%.

Majority of the domestic pharma stocks are trading in the green with Ranbaxy Laboratories and Piramal Enterprises being among major gainers.Aurobindo Pharma and Dishman Phrama are among the few stocks trading in the red. As per a leading financial daily, Lupin forayed into the Latin American market through the acquisition of a speciality pharmaceutical company Laboratorios Grin based in Mexico. Grin is engaged in the manufacture and sale of branded ophthalmic products and clocked revenues of around $28 m in 2013. The pharmaceutical market in Mexico is valued at over $13.5 bn and is growing at an annual rate of 9-10%. The company wants to bring its pipeline of ophthalmic products to build the Grin business as well as leverage their commercial presence to enter other potential therapy segments. Lupin's stock is currently trading up by 0.3%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets slip". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.